Cargando…
Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells
INTRODUCTION: Sustained HER2 signaling at the cell surface is an oncogenic mechanism in a significant proportion of breast cancers. While clinically effective therapies targeting HER2 such as mAbs and tyrosine kinase inhibitors exist, tumors overexpressing HER2 eventually progress despite treatment....
Autores principales: | Ren, Xiu-Rong, Wei, Junping, Lei, Gangjun, Wang, Jiangbo, Lu, Jiuyi, Xia, Wenle, Spector, Neil, Barak, Larry S, Clay, Timothy M, Osada, Takuya, Hamilton, Erika, Blackwell, Kimberly, Hobeika, Amy C, Morse, Michael A, Lyerly, H Kim, Chen, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446352/ https://www.ncbi.nlm.nih.gov/pubmed/22676470 http://dx.doi.org/10.1186/bcr3204 |
Ejemplares similares
-
Correction: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
por: Hamilton, Erika, et al.
Publicado: (2013) -
Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
por: Hamilton, Erika, et al.
Publicado: (2012) -
Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers
por: Osada, Takuya, et al.
Publicado: (2018) -
Perhexiline promotes HER3 ablation through receptor internalization and inhibits tumor growth
por: Ren, Xiu-Rong, et al.
Publicado: (2015) -
Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2
por: Morse, Michael A, et al.
Publicado: (2007)